The Editor’s Roundtable: Expanded Versus Standard Lipid Panels in Assessing and Managing Cardiovascular Risk

      This CME activity is supported by an educational grant from Quest Diagnostics, Madison, New Jersey.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        Circulation. 2002; 106: 3143-3421
        • Fruchart J.C.
        • Nierman M.C.
        • Stroes E.S.
        • Kastelein J.J.
        • Duriez P.
        New risk factors for atherosclerosis and patient risk assessment.
        Circulation. 2004; 109: III15
        • Ginsberg H.N.
        Lipoprotein physiology.
        Endocrinol Metab Clin North Am. 1998; 27: 503-519
        • Barter P.J.
        • Ballantyne C.M.
        • Carmena R.
        • Castro Cabezas M.
        • Chapman M.J.
        • Coutre P.
        • De Graf J.
        • Durrington P.N.
        • Faergeman O.
        • Frohlich J.
        • et al.
        ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
        J Intern Med. 2006; 259: 247-258
        • Barter P.J.
        • Rye K.A.
        The rationale for using apoA-1 as a clinical markers of cardiovascular risk.
        J Intern Med. 2006; 259: 447-454
        • Walldius G.
        • Jungner I.
        The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence.
        J Intern Med. 2006; 259: 493-519
        • Jungner I.
        • Sniderman A.D.
        • Furberg C.
        • Aastveit A.H.
        • Holme I.
        • Walldius G.
        Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?.
        Am J Cardiol. 2006; 97: 943-946
        • Ingelsson E.
        • Schaefer E.J.
        • Contois J.H.
        • McNamara J.R.
        • Sullivan L.
        • Keyes M.J.
        • Pencina M.J.
        • Schoonmaker C.
        • Wilson P.W.
        • D’Agostino R.B.
        • Vasan R.S.
        Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
        JAMA. 2007; 298: 776-785
        • Ridker P.M.
        • Rifai N.
        • Cook N.R.
        • Bradwin G.
        • Buring J.E.
        Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
        JAMA. 2005; 294: 326-333
        • van der Steeg W.A.
        • Boekholdt S.M.
        • Stein E.A.
        • El-Harchaoui K.
        • Stroes E.S.
        • Sandhu M.S.
        • Wareham N.J.
        • Jukema J.W.
        • Luben R.
        • Zwinderman A.H.
        • et al.
        Role of apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
        Ann Intern Med. 2007; 146: 640-648
        • Chapman M.J.
        • Guerin M.
        • Bruckert E.
        Atherogenic, dense low-density lipoproteins.
        Eur Heart J. 1998; 19: A24-A30
        • de Graaf J.
        • Hak-Lemmers H.L.
        • Hectors M.P.
        • Demacker P.N.
        • Hendriks J.C.
        • Stalenhoef A.F.
        Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
        Arterioscler Thromb Vasc Biol. 1991; 11: 298-306
        • Tribble D.L.
        • Holl L.G.
        • Wood P.D.
        • Krauss R.M.
        Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size.
        Atherosclerosis. 1999; 93: 189-199
        • Kontush A.
        • Chapman M.J.
        Antiatherogenic small, dense HDL—guardian angel of the arterial wall?.
        Nat Clin Pract Cardiovasc Med. 2006; 3: 144-153
        • Nordestgaard B.G.
        • Benn M.
        • Schnohr P.
        • Tybjærg-Hansen A.
        Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.
        JAMA. 2007; 298: 299-308
        • Bansal S.
        • Buring J.E.
        • Rifai N.
        • Mora S.
        • Sacks F.M.
        • Ridker P.M.
        Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.
        JAMA. 2007; 298: 309-316
        • Hokanson J.E.
        • Austin M.A.
        Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.
        J Cardiovasc Risk. 1996; 3: 213-219
        • Patel A.
        • Barzi F.
        • Jamrozik K.
        • Lam T.H.
        • Ueshima H.
        • Whitlock G.
        • Woodward H.
        • Asia Pacific Cohort Studies Collaboration
        Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region.
        Circulation. 2004; 110: 2678-2686
        • Nissen S.E.
        • Tsunoda T.
        • Tuzcu E.M.
        • Schoenhagen P.
        • Cooper C.C.J.
        • Yasin M.
        • Eaton G.M.
        • Lauer M.A.
        • Sheldon W.S.
        • Grines C.L.
        • et al.
        Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
        JAMA. 2003; 290: 2292-2300
        • Nicholls S.J.
        • Tuzcu E.M.
        • Sipahi I.
        • Schoenhagen P.
        • Crowe T.
        • Kapadia S.
        • Nissen S.E.
        Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-1 Milano.
        J Am Coll Cardiol. 2006; 47: 992-997
        • Brown B.G.
        • Zhao X.-Q.
        • Chait A.
        • Fisher L.D.
        • Cheung M.C.
        • Morse J.S.
        • Dowdy A.A.
        • Marino E.K.
        • Bolson E.L.
        • Alaupovic P.
        • et al.
        Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
        N Engl J Med. 2001; 345: 1583-1592
        • Rubin E.M.
        • Krauss R.M.
        • Spangler E.A.
        • Verstuyft J.G.
        • Clift S.M.
        Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A1.
        Nature. 1991; 353: 265-267
        • Kane J.P.
        • Malloy M.J.
        • Ports T.A.
        • Phillips N.R.
        • Diehl J.C.
        • Havel R.J.
        Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
        JAMA. 1990; 264: 3007-3012
        • Sniderman A.D.
        • Jungner I.
        • Holme I.
        • Aastveit A.
        • Walldius G.
        Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-1 ratio to identify the lipoprotein-related risk of vascular disease.
        J Intern Med. 2006; 259: 455-461
        • Brown B.G.
        • Albers J.J.
        • Fisher L.D.
        • Schaefer S.M.
        • Lin J.T.
        • Kaplan C.
        • Zhao X.-Q.
        • Bisson B.D.
        • Fitzpatrick V.F.
        • Dodge H.T.
        Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
        N Engl J Med. 1990; 323: 1289-1298
        • Maher V.M.
        • Brown B.G.
        • Marcovina S.M.
        • Hillger L.A.
        • Zhao X.Q.
        • Albers J.J.
        Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).
        JAMA. 1995; 274: 1771-1774
        • Shilpak M.G.
        • Simon A.
        • Vittinghoff E.
        • Lin F.
        • Barrett-Connor E.
        • Knopp R.H.
        • Levy R.I.
        • Hulley S.B.
        Estrogen and progestin, Lp(a) and the risk of recurrent coronary heart disease events after menopause.
        JAMA. 2000; 283: 1845-1852
        • Sniderman A.D.
        • Holme I.
        • Aastveit A.
        • Furberg C.
        • Walldius G.
        • Jungner I.
        Relation of age, the apolipoprotein b/apolipoprotein a-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease.
        Am J Cardiol. 2007; 100: 217-221
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • Dans T.
        • Avezum A.
        • Lanas F.
        • McQueen M.
        • Budaj A.
        • Pais P.
        • Varigos J.
        • Lisheng L.
        • INTERHEART Study Investigators
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
        Lancet. 2004; 364: 937-952
        • St. Pierre A.C.
        • Ruel I.L.
        • Cantin B.
        • Dagenais G.R.
        • Bernard P.M.
        • Després J.P.
        • Lamarche B.
        Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease.
        Circulation. 2001; 104: 2295-2299
        • Mukamal K.J.
        • Mackey R.H.
        • Kuller L.H.
        • Tracy R.P.
        • Kronmal R.A.
        • Mittleman M.A.
        • Siscovick D.S.
        Alcohol consumption and lipoprotein subclasses in older adults.
        J Clin Endocrinol Metab. 2007; 92: 2559-2566